Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 133 publications.
Skip to main content
Cha-Silva AS, Zhang KH, Graham C, Kurosky SK, Tran H, Law EH, Song EJ. A cost per responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe Alopecia Areata (AA). Poster presented at the ISPOR 2025; May 15, 2025. Montréal, Canada.
Nahas SJ, Zhao Y, Graham CN, Erbe A, Blumenfeld A. Comparative efficacy of AXS-07 vs. gepants for acute treatment of migraine: a network meta-analysis. Poster presented at the American Academy of Neurology (AAN) 2025 Annual Meeting; April 2025.
Graham C, Erbe A. Hospitalization costs of common grade 3/4 adverse events associated with oncology treatments in the United States: 2024 update. Poster presented at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain. [abstract] Value Health. 2024 Dec; 27(12 Supplement):S137. doi: 10.1016/j.jval.2024.03.730
Grace M, Wang K, Graham CN. Budget impact of injectafer (ferric carboxymaltose injection) for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity on a third-party US payer. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2024; October 14, 2024. Las Vegas, NV.
Winfree KB, Zhang KH, Muehlenbein CE, Panjic EH, Ale-Ali A, Graham CN. Budget impact of pirtobrutinib for patients with Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the United States (US). Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S143. doi: 10.1016/j.jval.2024.03.2236
Graham CN, Erbe AW. Hospitalization costs of common grade 3/4 adverse events associated with oncology treatments in the United States. Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S137. doi: 10.1016/j.jval.2024.03.730
Zhang K, Shah C, Graham C, McBayne T, Schultz B. A cost model comparing long-term prophylaxis options for hereditary angioedema: lanadelumab and berotralsta. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2023 Oct; 29(10-a Suppl):S39. doi: 10.18553/jmcp.2023.29.10-a.s1
Hamadani M, Graham C, Liao L, Zhang K, Strat HM, Ungar D, Ai W, Chen L, Carlo-Stella C. Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2022 Jun;40(16_suppl):e19551.
Graham CN, Watson C, Barlev A, Stevenson M, Dharnidharka VT. Mean lifetime survival estimates following solid organ transplantation in the US and UK. J Med Econ. 2022 Jan;25(1):230-7. doi: 10.1080/13696998.2022.2033050
Graham C. A new approach to survival curve tail corrections: the Age-Matched Life Table (AMLT) Method. Poster presented at the Virtual ISPOR 2021 Conference; May 2021.
Augustin M, McBride D, Gilloteau I, O'Neill C, Neidhardt K, Graham CN. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2191-9. doi: 10.1111/jdv.15047
Warren RB, Halliday A, Graham CN, Gilloteau I, Miles L, McBride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2178-84. doi: 10.1111/jdv.15094
Bianculli PM, Salibe M, Peirano I, Gilloteau I, Graham C. Secukinumab as first biologic treatment: a cost per responder analysis compared with licensed biologics, for moderate to severe psoriasis in Argentina. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Suzuki C, Lopes N, Gilloteau I, Graham C. Cost per responder of secukinumab compared to other biologics in moderate-to-severe plaque psoriasis from the private payer perspective in Brazil. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Kooli A, Graham C, Scheuer N, Gilloteau I, Miles L, Sherif B, McBride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared to ustekinumab and etanercept in Morocco. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Kooli A, Graham C, Scheuer N, Gilloteau I, Miles L, Sherif B, McBride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared to ustekinumab and etanercept in Tunisia. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Graham CN, Christodoulopoulou A, Knox HN, Sabatelli L, Hechmati G, Garawin T, Strickler JH. A within-trial cost-effectiveness analysis of panitumumab compared with bevacizumab in the first-line treatment of patients with wild-type RAS metastatic colorectal cancer in the US. J Med Econ. 2018 Nov;21(11):1075-83. doi: 10.1080/13696998.2018.1510409.
Igarashi A, Igarashi AS, Graham CN, Gilloteau I, Tani Y. Evaluating the cost-effectiveness of secukinumab in moderate to severe psoriasis: a Japanese perspective. J Med Econ. 2018 Oct 26;22(1):7-15. doi: 10.1080/13696998.2018.1532905.
Emery P, van Keep M, Beard S, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Marzo-Ortega H. Cost effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. Pharmacoeconomics. 2018 Aug;36(8):1015-27. doi: 10.1007/s40273-018-0675-9
Feldman SR, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V. Higher psoriasis skin clearance is associated with lower annual indirect costs in the United States: a post hoc analysis from the CLEAR Study. J Manag Care Spec Pharm. 2018 Jul;24(7):617-22. doi: 10.18553/jmcp.2018.24.7.617
Buchanan V, Sullivan W, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Kirkham B. Cost effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Pharmacoeconomics. 2018 Jul;36(7):867-78. doi: 10.1007/s40273-018-0674-x.
Suzuki C, Lopes N, Tozato C, Gilloteau I, Graham CN. Cost-effectiveness of secukinumab compared to other biologics in moderate-to-severe plaque psoriasis from a Brazilian perspective. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD.
Suzuki C, Lopes N, Tozato C, Gilloteau I, Graham CN. Cost per responder of secukinumab compared to other biologics in moderate-to-severe plaque psoriasis in Brazil. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S240. doi: 10.1016/j.jval.2018.04.1633
Graham C, McGuire M, Knox H, Ung B. Budget impact analysis of enasidenib treatment in patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 mutation. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S31.
Krishnarajah G, Knox H, Graham CN, Christiansen S, Zuraw B. Subcutaneous C1-inhibitor prophylactic treatment for hereditary angioedema: a budget impact model. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 23, 2018. Boston, MA. [abstract] J Manag Care Pharm. 2018 Apr; 24(4-a):S37.
Goeree R, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM, Gladman DD. Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. J Med Econ. 2018 Feb;21(2):163-73. doi: 10.1080/13696998
Maiese E, Graham CN, Hawe E, Le Moine JG. Cost per median month of progression-free survival for daratumumab plus bortezomib and dexamethasone compared with carfilzomib plus dexamethasone in relapsed/refractory multiple myeloma. Poster presented at the 2018 ASCO Annual Meeting; June 1, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018; p.e20037. doi: 10.1200/JCO.2018.36.15_suppl.e20037
Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Castor Trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 10, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):3400. doi: 10.1182/blood.V130.Suppl_1.3400.3400
Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Pollux trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 11, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):4711. doi: 10.1182/blood.V130.Suppl_1.4711.4711
Kuznik A, Bego-Le-Bagousse G, Eckert L, Gadkari A, Simpson E, Graham CN, Miles L, Mastey V, Mahajan P, Sullivan SD. Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. Dermatol Ther. 2017 Dec;7(4):493-505. doi: 10.1007/s13555-017-0201-6
Warren R, Halliday A, Graham CN, Gilloteau I, Miles L, Sherif B, McBride D. Secukinumab significantly reduces work impairment and indirect costs compared to ustekinumab and etanercept in the United Kingdom. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland.
Emery P, van Keep M, Beard SM, Graham CN, Miles L, Jugl SM, Gunda P, Halliday A, Marzo-Ortega H. Cost-effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland.
Chiva-Razavi S, Jain M, Graham CN, Miles L, Nikoglou E, Gunda P. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis: a Canadian perspective. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland.
Kirkham B, Buchanan V, Sullivan W, Graham CN, Miles L, Jugl SM, Gunda P, Halliday A. Cost-effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 6, 2017. Glasgow, Scotland.
Graham CN, McBride D, Miles L, Gilloteau I, O'Neill CB, Neidhardt K, Augustin M. Cost-effectiveness of secukinumab in moderate to severe psoriasis compared with other biologics in Germany. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A157.
Augustin M, Graham CN, Miles L, Gilloteau I, O'Neill CB, Neidhardt K, McBride D. A cost-per-responder analysis of secukinumab compared with ustekinumab through 52 weeks in Germany: results from the clear study of patients with moderate to severe psoriasis. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A158.
Sherif B, Graham CN, Neidhardt K, Gilloteau I, O'Neill CB, McBride D, Augustin M. EQ-5D-3L utilities tariffs: differences in German and UK utilities and QALYS in patients with moderate to severe psoriasis. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A331.
Goeree R, Gladman D, Chiva-Razavi S, Gunda P, Graham CN, Miles L, Nikoglou E, Jugl SM. Cost-effectiveness analysis of secukinumab in psoriatic arthritis: a Canadian perspective. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A145.
Marzo-Ortega H, Halliday A, Jugl S, Mokashi S, Gunda P, Graham CN, Miles L, Beard S, van Keep M. The cost-effectiveness of secukinumab versus tumour necrosis factor alpha inhibitor biosimilars for ankylosing spondylitis in the UK. Poster presented at the British Society for Rheumatology 2017; April 25, 2017. Birmingham, United Kingdom.
Augustin M, Krieger T, McBride D, Graham C, Melzer N, Kneidl J, Gutknecht M, Neidhardt K. Kosten-effektivität von secukinumab in der induktionstherapie der psoriasis in Deutschland. Poster presented at the 49th German Society of Dermatology (DDG) Conference; April 26, 2017. Berlin, Germany. [abstract] J Dtsch Dermatol Ges. 2017 Apr; 15(S1):130-1. doi: 10.1111/ddg.13213